Catalyst Pharmaceuticals Inc (CPRX)

Pretax margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm) US$ in thousands 94,511 80,812 144,840 124,573 104,719 84,524 72,589 60,244 52,667 48,578 46,243 40,736 41,890 41,572 44,074 45,091 33,410 10,504 -11,574 -28,949
Revenue (ttm) US$ in thousands 398,204 348,393 302,949 256,480 214,203 191,755 170,465 153,717 140,833 133,539 126,902 120,142 119,073 118,181 119,761 118,994 102,306 72,683 41,786 12,948
Pretax margin 23.73% 23.20% 47.81% 48.57% 48.89% 44.08% 42.58% 39.19% 37.40% 36.38% 36.44% 33.91% 35.18% 35.18% 36.80% 37.89% 32.66% 14.45% -27.70% -223.58%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $94,511K ÷ $398,204K
= 23.73%

The pretax margin for Catalyst Pharmaceuticals Inc has shown fluctuating trends over the past several quarters. The pretax margin represents the company's profitability before tax expenses are deducted, indicating the percentage of revenue that translates into pre-tax profits.

In the most recent quarter of December 31, 2023, the pretax margin stood at 23.73%, reflecting a moderate level of profitability. This was slightly higher than the previous quarter's pretax margin of 23.20% in September 30, 2023.

Notably, there was a significant increase in pretax margin in the quarter ending June 30, 2023, where it reached 47.81%, indicating a substantial improvement in profitability. This positive trend continued into the following quarter on March 31, 2023, with a pretax margin of 48.57%.

Looking back further, the pretax margin had been relatively stable around the 40% range up to June 30, 2022. There was a slight dip in profitability in the subsequent quarters, but the company managed to maintain pretax margins above 30% for the most part.

It is important to highlight a substantial decline in profitability in the last quarter of 2019 and the first quarter of 2020, where the pretax margins were at 32.66% and 14.45%, respectively. Furthermore, the performance in the first quarter of 2019 and the fourth quarter of 2019 showed negative pretax margins of -27.70% and -223.58%, indicating significant losses during those periods.

Overall, the pretax margin trend for Catalyst Pharmaceuticals Inc has demonstrated variability, with both periods of strong profitability and challenges. The company's ability to maintain and improve pretax margins will be crucial in sustaining long-term financial health and profitability.